H.C. Wainwright analyst Swayampakul Ramakanth lowered the firm’s price target on ALX Oncology to $16 from $30 and keeps a Buy rating on the shares post the Q2 report. The company announced the termination of its ASPEN-02 and ASPEN-05 studies that evaluate evorpacept as a combination agent for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia, respectively, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALXO:
- ALX Oncology reports Q2 EPS (84c), consensus (88c)
- ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
- ALX Oncology receives orphan drug designation from EC for evorpacept
- ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer
- Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call